WO2009098019A2 - Préparations de soins pour peau stressée - Google Patents

Préparations de soins pour peau stressée Download PDF

Info

Publication number
WO2009098019A2
WO2009098019A2 PCT/EP2009/000681 EP2009000681W WO2009098019A2 WO 2009098019 A2 WO2009098019 A2 WO 2009098019A2 EP 2009000681 W EP2009000681 W EP 2009000681W WO 2009098019 A2 WO2009098019 A2 WO 2009098019A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin care
ellagic acid
preparation according
care preparation
skin
Prior art date
Application number
PCT/EP2009/000681
Other languages
German (de)
English (en)
Other versions
WO2009098019A4 (fr
WO2009098019A3 (fr
Inventor
Volker Achterberg
Andrea Heuer
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP09708395A priority Critical patent/EP2249766A2/fr
Publication of WO2009098019A2 publication Critical patent/WO2009098019A2/fr
Publication of WO2009098019A3 publication Critical patent/WO2009098019A3/fr
Publication of WO2009098019A4 publication Critical patent/WO2009098019A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the present invention relates to preparations for the care of stressed or slightly injured irritated skin.
  • Known skincare preparations usually contain oils or waxes which occlusively cover the skin and thus cover light lesions / fissures such as occur during shaving or in babies in the diaper area. The leakage of blood and wound exudate is thus physically stopped and hemostasis naturally occurs after some time.
  • Alaunkynite For faster attenuation or stopping of the escape of blood and wound exudate of the micro-lesions of the skin occurring during shaving, there are so-called Alaunkynite with which the wound is treated.
  • Alum has a strong astringent effect, which leads to a contraction of the tissue and thus to stopping the bleeding.
  • alum irritates the skin, so that the application is unpleasant, sometimes painful.
  • the diaper area is not limited to the regions that come in contact with the excrement.
  • the diaper area also includes the skin areas, which are covered by cuffs or elastic bands of diapers and can be scoured by them.
  • the object of the present invention is therefore to avoid the disadvantages of the prior art and to find a low-cost substance of plant origin, which is stable in skin care preparations and leads to the reduction of the time until the onset of hemostasis.
  • the present invention therefore relates to skin care preparations, in particular oil-in-water emulsions, hydrogels or aqueous gels which have an effective concentration of ellagic acid.
  • Ellagic acid is a polyphenol having a molecular weight of 338.2 g / mol and the following structure:
  • ellagic acid is found in significant concentrations of up to 1% in many plants and woody plants. These include raspberries, pomegranates, strawberries, blackberries, walnuts and many other fruits and nuts. Together with gallic acid, it is also found in rose plants. By acid hydrolysis, the ellagtannin decomposes, inter alia, in ellagic acid. In water, ellagic acid is only sparingly soluble, but it dissolves in ethanol, dilute alkalis, and pyridine.
  • Ellagic acid is also known as a component of diagnostics for the investigation of the intrinsic pathway of blood clotting. It promotes fibrin formation, assuming that ellagic acid is responsible for surface activation. (T.Exner & K. A. Rickard, Thromb. Res. 26 (1982), 83-89; A. Girolami et al., Blood 27 (1966), 93-102).
  • the poor solubility of the ellagic acid causes the addition of the ellagic acid in the preparation of the skin care preparation as a suspension. Even when homogenizing the ellagic acid dissolves only to a small extent and is at least partially particulate in the finished skincare preparation.
  • the sources of ellagic acid are advantageously and preferably natural sources.
  • the ellagic acid is prepared from natural sources, in particular from purified extracts of ellagic acid-containing plant parts, in particular from fruits.
  • the extraction of active ingredients from plant parts has been familiar to the expert for centuries. Usually, the extraction is carried out with polar solvents such as ethanol, acetone or ethyl acetate with subsequent hydrolysis and filtration.
  • polar solvents such as ethanol, acetone or ethyl acetate with subsequent hydrolysis and filtration.
  • the production of pomegranate extracts is described in MN Aslam et al. (J. Ethnopharmacol., 103 (2006), 311-318) and can be transferred to other plant nutrient-containing plant material.
  • extracts or the ellagic acid purified therefrom are commercially available, for example from Wagott (Chengdu / China), Ingredientrade Europe (New York / USA) or AMC / Premium Ingredients (
  • ellagic acid obtained from pomegranates is particularly advantageous for the blood and secretion-calming effect.
  • the coagulation process is accelerated compared to pure, synthetically produced ellagic acid.
  • Ellagic acid is characterized by a very poor solubility in water, so that the effect depends very much on the free surface. To produce the largest possible surfaces it is therefore within the meaning of the invention to treat the ellagic acid-containing suspensions prior to addition with ultrasound in order to achieve a finer distribution as possible below 5 microns.
  • the skin care preparation according to the invention is preferably an O / W emulsion or an aqueous gel.
  • the content of skin care preparations containing ellagic acid should be between 0.001 and 0.1% by weight, based on the total weight of the preparation, in particular between 0.01 and 0.05% by weight.
  • a very particularly advantageous embodiment of the skin care preparations according to the invention are sprayable skin care preparations which can be applied to the skin without heavy rubbing.
  • a particular embodiment of these sprayable preparations can be used similar to a spray plaster.
  • Sprayable skin care preparations according to the invention should have a viscosity of less than 5,000 mPas, in particular less than 2,500 mPas.
  • the skin care preparation contains microbicides, in particular bactericides, virucides, fungicides or antibiotics, and thus the regeneration of the skin can proceed without problems. It is also possible that the skin care preparation of the invention contains substances that have skin-moisturizing properties, such. As diols and / or polyols, urea, hyaluronic acid or glyceryl glucose, or substances with filtersuitn- properties contains such. As panthenol, creatine, zinc, vitamin C or vitamin E.
  • the powdery substances were suspended in phosphate buffered saline (PBS) at a concentration of 3.4 mg / ml (10 mmol / l) and used as a finely dispersed suspension either directly or after sonication (sonic bath, in ice for 30 min). Thereafter, the suspensions were diluted with PBS 1: 100 to a concentration of 34 ⁇ g / ml (0.1 mmol / l) of ellagic acid, based on pure ellagic acid.
  • PBS phosphate buffered saline
  • the test is carried out in accordance with ISO 10993-4, part B3, with citrated blood (CB).
  • Thromboelastography is a global assay for quantifying blood clotting of whole blood (J.A. Caprini et al., 'Perspectives on thromboelastography', Semin Thromb, Hemost 21 (Suppl. 4, 1995), 91-93).
  • the main measurement parameter is the clotting time: the time to fibrin clot formation. Hemostatic substances shorten the fibrin formation time.
  • the starting suspension of the ultrasound-treated ellagic acid (10 mmol / l) described in Example 1 was diluted with the skincare preparation 1:10 to a concentration of 338 ⁇ g / ml (1 mmol / l). To ensure a good distribution, the batch was mixed for about 1 min with a vortex shaker.
  • the clot formation time was reduced to 50% of the control value (citrated blood with PBS) by pomegranate ellagic acid doping (A3). Only a small reduction to 90% of the control value was found with the corresponding pure, synthetic ellagic acid ( Figure 3).
  • the above-described ellagic acid-doped skincare preparations were examined by means of thromboelastography. The corresponding skincare preparation was mixed with 2.8 ml of citrated blood, swirled, and a sample of the test piece in the thromboelastograph was examined. The clot formation time was reduced to 28% by doping with pomegranate ellagic acid (A3) and only 91% with pure synthetic ellagic acid (B3) compared to CB + PBS ( Figure 4).
  • Figures 1 to 4 graphically reproduce the experimental results of Examples 1 and 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations de soins pour peau stressée ou peau irritée, légèrement lésée.
PCT/EP2009/000681 2008-02-07 2009-02-03 Préparations de soins pour peau stressée WO2009098019A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09708395A EP2249766A2 (fr) 2008-02-07 2009-02-03 Préparations de soins pour peau stressée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008008540A DE102008008540A1 (de) 2008-02-07 2008-02-07 Hautpflegezubereitung zur Pflege von gestresster Haut
DE102008008540.5 2008-02-07

Publications (3)

Publication Number Publication Date
WO2009098019A2 true WO2009098019A2 (fr) 2009-08-13
WO2009098019A3 WO2009098019A3 (fr) 2009-11-05
WO2009098019A4 WO2009098019A4 (fr) 2009-12-23

Family

ID=40847371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000681 WO2009098019A2 (fr) 2008-02-07 2009-02-03 Préparations de soins pour peau stressée

Country Status (3)

Country Link
EP (1) EP2249766A2 (fr)
DE (1) DE102008008540A1 (fr)
WO (1) WO2009098019A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110327227A (zh) * 2019-08-01 2019-10-15 上海应用技术大学 一种含有鞣花酸的水凝胶微球及其制备方法
CN114028332A (zh) * 2021-12-02 2022-02-11 南京中医药大学 一种鞣花酸纳米混悬液及其在口服、外用制剂和化妆品中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294808A1 (fr) * 1987-06-09 1988-12-14 Lion Corporation Agent pour application externe et son emploi
WO1991016453A1 (fr) * 1990-04-17 1991-10-31 Analytical Control Systems, Inc. Titrages et reactifs de coagulation
EP0496173A1 (fr) * 1991-01-22 1992-07-29 Synthelabo Extraits de Noix d'Alep, leur préparation et leurs applications
DE19730408A1 (de) * 1996-07-16 1998-03-05 Lion Corp Zusammensetzung für äußere Anwendung
FR2768927A1 (fr) * 1997-10-01 1999-04-02 Lvmh Rech Utilisation de l'acide ellagique, de ses sels, de ses complexes metalliques, de ses derives mono- ou poly-ethers, mono- ou poly-acyles dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
WO2007004229A2 (fr) * 2005-07-06 2007-01-11 Rimonest Ltd. Methodes d'utilisation de fractions de grenades pour reparer la peau
FR2893505A1 (fr) * 2005-11-23 2007-05-25 Oreal Dispersion aqueuse d'acide ellagique et son utilisation en cosmetique
JP2008075221A (ja) * 2006-09-22 2008-04-03 Nicca Chemical Co Ltd 洗濯用皮膚保護性仕上げ剤、及びそれを用いた皮膚保護性付与方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055412A (en) * 1989-03-21 1991-10-08 Proksch Gary J Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same
JP3923226B2 (ja) * 1998-12-28 2007-05-30 ライオン株式会社 皮膚外用剤
US20020082220A1 (en) * 2000-06-29 2002-06-27 Hoemann Caroline D. Composition and method for the repair and regeneration of cartilage and other tissues
JP2003160461A (ja) * 2001-11-21 2003-06-03 Shiseido Co Ltd 皮膚外用剤
US20070237834A1 (en) * 2003-04-18 2007-10-11 Bioderm Research Zinc Zeolite for the Treatment for Diaper Rash (Diaper Dermatitis)
JP2006070016A (ja) * 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0294808A1 (fr) * 1987-06-09 1988-12-14 Lion Corporation Agent pour application externe et son emploi
WO1991016453A1 (fr) * 1990-04-17 1991-10-31 Analytical Control Systems, Inc. Titrages et reactifs de coagulation
EP0496173A1 (fr) * 1991-01-22 1992-07-29 Synthelabo Extraits de Noix d'Alep, leur préparation et leurs applications
DE19730408A1 (de) * 1996-07-16 1998-03-05 Lion Corp Zusammensetzung für äußere Anwendung
FR2768927A1 (fr) * 1997-10-01 1999-04-02 Lvmh Rech Utilisation de l'acide ellagique, de ses sels, de ses complexes metalliques, de ses derives mono- ou poly-ethers, mono- ou poly-acyles dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
WO2007004229A2 (fr) * 2005-07-06 2007-01-11 Rimonest Ltd. Methodes d'utilisation de fractions de grenades pour reparer la peau
FR2893505A1 (fr) * 2005-11-23 2007-05-25 Oreal Dispersion aqueuse d'acide ellagique et son utilisation en cosmetique
JP2008075221A (ja) * 2006-09-22 2008-04-03 Nicca Chemical Co Ltd 洗濯用皮膚保護性仕上げ剤、及びそれを用いた皮膚保護性付与方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Ellagic acid" WIKIPEDIA, THE FREE ENCYCLOPEDIA, [Online] 15. Januar 2008 (2008-01-15), XP002539090 Gefunden im Internet: URL:http://web.archive.org/web/20080115164135/http://en.wikipedia.org/wiki/Ellagic_acid> [gefunden am 2009-07-28] *
CHRISTINE THIELEN: "Auswahl und Verarbeitung von Früchten zur Steigerung der Gehalte an phenolischen Antioxidantien in Fruchtsäften" DISSERTATION, [Online] 2006, XP002539408 Kaiserslautern Gefunden im Internet: URL:http://kluedo.ub.uni-kl.de/volltexte/2006/1925/pdf/Thielen.pdf> [gefunden am 2009-07-30] *
N.P. SEERAM: "In vitro antiproliferative,apoptotic and antioxidant activities of punicalagin ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice" JOURNAL OF NUTRITIONAL BIOCHEMISTRY, [Online] Bd. 16, Nr. 06, Juni 2005 (2005-06), Seiten 360-367, XP002539437 Gefunden im Internet: URL:http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T8P-4G9PC5N-7&_user=987766&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000049880&_version=1&_urlVersion=0&_userid=987766&md5=24510bae78735b4c72d8a164bf7af7b6> [gefunden am 2009-07-30] *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110327227A (zh) * 2019-08-01 2019-10-15 上海应用技术大学 一种含有鞣花酸的水凝胶微球及其制备方法
CN114028332A (zh) * 2021-12-02 2022-02-11 南京中医药大学 一种鞣花酸纳米混悬液及其在口服、外用制剂和化妆品中的应用
CN115737553A (zh) * 2021-12-02 2023-03-07 南京中医药大学 一种高溶解度和抗氧化活性的鞣花酸纳米混悬剂及其在口服、外用制剂和化妆品中的应用

Also Published As

Publication number Publication date
EP2249766A2 (fr) 2010-11-17
WO2009098019A4 (fr) 2009-12-23
WO2009098019A3 (fr) 2009-11-05
DE102008008540A1 (de) 2009-08-13

Similar Documents

Publication Publication Date Title
DE69426064T2 (de) Kosmetische Zusammensetzung enthaltend einen pflanzlichen extrazellularen Matrixextrakt
DE10084749B4 (de) Substrat, welches mit einer Zusammensetzung behandelt ist, die einen botanischen Extrakt und ein Tensid enthält, sowie Körperpflegeartikel, welcher das behandelte Substrat enthält
DE69730835T2 (de) Methode zur verhinderung von hautreizungen durch fäkale enzyme
DE1617317B2 (de) Knorpelmasse
WO2014009118A1 (fr) Composition contenant, en tant que principe actif, de l'ectoïne ou de l'hydroxyectoïne pour la reconstruction de tissus corporels lésés
CN110575412A (zh) 一种添加药用孔菌层提取物的毛孔专用美容液及其制备方法
JP4658631B2 (ja) 入浴剤組成物
WO2000038647A1 (fr) Agents pour proteger la peau, contenant un melange de fragments produit par hydrolyse a partir d'acide hyaluronique
DE69328228T2 (de) Wundheilmittel
DE69121405T2 (de) Verfahren zur verminderung der reizenden eigenschaften von kosmetischen zusammensetzungen
DE69205839T2 (de) Dermatologische und kosmetische Zusammensetzung.
WO2009098019A2 (fr) Préparations de soins pour peau stressée
KR102153738B1 (ko) 멍 제거용 화장료 조성물, 이를 포함하는 멍 제거용 패치 및 상기 패치의 제조방법
CN107440920A (zh) 一种深层螯合美容洁面面膜及制备方法
CN115444766B (zh) 一种具有头皮滋养功效的双组分洗发水及其制备方法
DE2625289A1 (de) Verfahren zur herstellung eines sterilen kollagenproduktes mit filz- bzw. vliesartiger faserstruktur
KR20170099096A (ko) 피부 주름 개선용 화장료 조성물
KR102392617B1 (ko) 항균 및 항바이러스 조성물 및 이를 포함하는 피부 보습제
DE3330628A1 (de) Hautschutz- und -pflegelotion
DE1492023C3 (de) Hautpflegemittel
DE102008008537A1 (de) Wundversorgungsartikel
KR100444196B1 (ko) 나노리포좀으로 안정화된 약용식물 복합 추출액 함유화장료 조성물
CN109010105A (zh) 一种多效合一的组合物及其制备方法和应用
DE2653595C2 (de) Verfahren zum Extrahieren von embryonaler Kälberhaut, der dabei erhaltene Extrakt sowie dessen Verwendung als Wirkstoff in Mitteln zur Behandlung der Haut
WO2013135854A1 (fr) Produits cosmétiques pour peaux matures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708395

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009708395

Country of ref document: EP